Noninfectious interstitial lung disease during infliximab therapy: Case report and literature review

Table 1 Analysis of the bronchoalveolar lavage fluid

	Cells (106/L)	Macrophages	Lymphocytes	Neutrophils	Eosinophils
Patient	213	66%	13%	1%	20%
Ref. values	120-190	85%-93%1	5%-12%1	2%1	< 1%1

¹According to Meyer[16].

Table 2 Spirometric values during the follow up

	4-wkfollow up	8-wkfollow up	12-wkfollow up
FEV1, L	2.03 (58%)	2.24 (64%)	2.56 (73%)
FVC, L	2.08 (52%)	2.33 (58%)	2.62 (66%)
TLC, L	3.04 (56%)	3.63 (67%)	3.73 (69%)
RV, L	0.91 (62%)	1.30 (88%)	0.97 (66%)
FRC, L	1.62 (57%)	2.47 (87%)	2.44 (86%)
DLCO, mL/mmHg per minute	NA	17.3 (58%)	19.0 (64%)

FEV1: Forced expiratory volume in one second; FVC: Forced vital capacity; TLC: Total lung capacity; RV: Residual volume; FRC: Functional residual capacity; DLCO: Diffusion capacity of carbon monoxide; NA: Not available.